Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

Immunotherapies have shaped the cancer research space over the past decade, proving effective for the treatment of some ...

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

Roche will acquire Poseida Therapeutics, building on a partnership for CAR T-cell therapies in development for MS and other ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR ... with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

The study reveals IL-15's role in enhancing GPC3 CAR T cell therapy, improving tumor targeting and T cell survival in ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.